CN106999564A - 针对登革热病毒疾病的疫苗组合物 - Google Patents

针对登革热病毒疾病的疫苗组合物 Download PDF

Info

Publication number
CN106999564A
CN106999564A CN201580046426.3A CN201580046426A CN106999564A CN 106999564 A CN106999564 A CN 106999564A CN 201580046426 A CN201580046426 A CN 201580046426A CN 106999564 A CN106999564 A CN 106999564A
Authority
CN
China
Prior art keywords
dengue
composition
dengue fever
virus
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580046426.3A
Other languages
English (en)
Chinese (zh)
Inventor
N.托尔尼波思
A.布克努赫
F.诺里加
M.萨维尔
N.杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Publication of CN106999564A publication Critical patent/CN106999564A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201580046426.3A 2014-09-02 2015-09-02 针对登革热病毒疾病的疫苗组合物 Pending CN106999564A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14306350.1 2014-09-02
EP14306350 2014-09-02
EP15305851 2015-06-04
EP15305851.6 2015-06-04
PCT/EP2015/070060 WO2016034629A1 (en) 2014-09-02 2015-09-02 Vaccine compositions against dengue virus diseases

Publications (1)

Publication Number Publication Date
CN106999564A true CN106999564A (zh) 2017-08-01

Family

ID=54064325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580046426.3A Pending CN106999564A (zh) 2014-09-02 2015-09-02 针对登革热病毒疾病的疫苗组合物

Country Status (14)

Country Link
US (1) US10946087B2 (enExample)
EP (1) EP3188751A1 (enExample)
JP (1) JP2017526689A (enExample)
KR (2) KR20170043660A (enExample)
CN (1) CN106999564A (enExample)
AU (1) AU2015310951A1 (enExample)
BR (1) BR112017004197A2 (enExample)
CA (1) CA2958949A1 (enExample)
MX (1) MX2017002794A (enExample)
MY (1) MY192739A (enExample)
PH (1) PH12017500304A1 (enExample)
SG (1) SG11201701256RA (enExample)
TW (1) TWI852899B (enExample)
WO (1) WO2016034629A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555113A (zh) * 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913435TA (en) 2013-03-15 2020-03-30 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
SG10201913383RA (en) 2016-04-13 2020-03-30 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
SG11202102104SA (en) 2018-09-05 2021-04-29 Takeda Vaccines Inc Dengue vaccine unit dose and administration thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202201A (zh) * 1995-11-14 1998-12-16 巴斯德研究所 抗登革热的多价疫苗
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
AU2002322026B2 (en) 2001-06-01 2008-03-13 Acambis Inc. Chimeric flavivirus vectors
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
KR101536612B1 (ko) 2005-06-17 2015-07-14 사노피 파스퇴르 약독화된 뎅기 혈청형 1 균주
KR20080018271A (ko) 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CA2676775A1 (en) 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
BRPI0913012B1 (pt) 2008-04-30 2021-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102573891B (zh) 2009-07-29 2016-06-01 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
CN102906266A (zh) 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
ITMI20121231A1 (it) * 2012-07-16 2014-01-17 St Microelectronics Srl Metodo di controllo burst-mode per basso consumo in ingresso in convertitori risonanti e relativo dispositivo di controllo
AU2013295014B2 (en) 2012-07-24 2018-01-18 Sanofi Pasteur Vaccine compositions
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) * 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202201A (zh) * 1995-11-14 1998-12-16 巴斯德研究所 抗登革热的多价疫苗
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID E CLEMENTS等: "Development of a Recombinant Tetravalent Dengue Virus Vaccine: Immunogenicity and Efficacy Studies in Mice and Monkeys", 《VACCINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555113A (zh) * 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法

Also Published As

Publication number Publication date
BR112017004197A2 (pt) 2017-12-12
CA2958949A1 (en) 2016-03-10
KR20170043660A (ko) 2017-04-21
WO2016034629A1 (en) 2016-03-10
TWI852899B (zh) 2024-08-21
EP3188751A1 (en) 2017-07-12
MY192739A (en) 2022-09-06
US10946087B2 (en) 2021-03-16
SG11201701256RA (en) 2017-03-30
AU2015310951A1 (en) 2017-03-16
JP2017526689A (ja) 2017-09-14
KR20230170812A (ko) 2023-12-19
MX2017002794A (es) 2017-06-14
PH12017500304A1 (en) 2017-07-10
TW201620546A (zh) 2016-06-16
US20170304426A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
TWI852899B (zh) 疫苗組合物
JP6830118B2 (ja) ワクチン組成物
TWI406673B (zh) 對抗４種登革熱血清型之免疫方法
US20150265695A1 (en) Vaccine compositions for prevention against dengue virus infection
US20230338504A1 (en) Compositions for Booster Vaccination Against Dengue
WO2014083194A1 (en) Methods for inducing antibodies
HK1242193A1 (en) Vaccine compositions against dengue virus diseases
CA2878682C (en) Vaccine compositions for use in a method of protecting a human subject against dengue disease
HK1212906B (en) Vaccine compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242193

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1242193

Country of ref document: HK